title: Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.
abstract: 11C-Methionine (MET) is a useful positron emission tomography (PET) tracer for the evaluation of low-grade gliomas. Among these tumors, a high percentage of low-grade oligodendrogliomas (ODG) are sensitive to chemotherapy with procarbazine, CCNU, and vincristine (PCV). We aimed at: (1) objectively assessing ODG response to PCV by a metabolic index (the Activity Volume Index or AVI) generated from an automated semi-quantification of PET with MET (PET-MET); (2) comparing AVI and quantitative magnetic resonance imaging (MRI) measurements of response to PCV.
  
  
  METHODS
  seven patients with ODG were followed for a period of 19.9+/-6.6 months after the completion of PCV chemotherapy. Regions of interest (ROI) were generated by covering all voxels with count values above a threshold level set at 120% of the mean cerebellar activity. On each slice, ROI volume and mean count values were calculated. AVI was calculated as the sum over all ROI of tumor volumex(tumor mean count/cerebellum count). Tumor volume measurements on MRI, were based on signal abnormalities visually detected on fluid-attenuated inversion recovery (FLAIR) sequences.
  
  
  RESULTS
  PCV therapy was associated with a drastic decrease in AVI (mean+/-SD, cm3): AVI post-PCV=0.80+/-1.45 vs. AVI prior PCV=12.94+/-11.46 (P=0.03). Likewise, we observed a decrease in tumor volume estimated from the FLAIR signal (31.37+/-11.99 post-PCV vs. 67.95+/-39.96 prior PCV, P=0.03) although AVI decrease after PCV was significantly more pronounced (P=0.015).
  
  
  CONCLUSIONS
  This study, based on limited number of patients and follow-up period indicates that AVI may be a sensitive and observer-independent method applicable to the assessment of ODG responsiveness to PCV treatment and may offer a major added value to both clinical assessment and MRI evaluation of chemotherapeutic outcomes.
authors.affiliation: Department of Nuclear Medicine and PET/Biomedical-Cyclotron Unit, Université Libre de Bruxelles-Hôpital Erasme, Brussels, Belgium. Thanh.Tang@ulb.ac.be
authors.forename: Bich-Ngoc-Thanh
authors.initials: BN
authors.lastname: Tang
authors.forename: Niloufar
authors.initials: N
authors.lastname: Sadeghi
authors.forename: Fabrice
authors.initials: F
authors.lastname: Branle
authors.forename: Olivier
authors.initials: O
authors.lastname: De Witte
authors.forename: David
authors.initials: D
authors.lastname: Wikler
authors.forename: Serge
authors.initials: S
authors.lastname: Goldman
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008715:Methionine / Q000493:pharmacokinetics*; D008875:Middle Aged; D009837:Oligodendroglioma / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D049268:Positron-Emission Tomography; D011344:Procarbazine / Q000627:therapeutic use*; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use*
chemical_list: D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine; D008715:Methionine